**National Notifiable Diseases Surveillance System (NNDSS)**

**OMB Control Number 0920-0728**

**Expiration Date: 07/31/2025**

**Program Contact**

Umed A. Ajani

Associate Director for Science

Division of Health Informatics and Surveillance

Center for Surveillance, Epidemiology and Laboratory Services

Centers for Disease Control and Prevention

1600 Clifton Rd, MS-E91

Atlanta, GA 30329

Phone: (404) 498-0258

E-mail: [uajani@cdc.gov](mailto:uajani@cdc.gov)

**Submission Date:** August 2, 2022

**Circumstances of Change Request for OMB 0920-0728**

This is a non-substantive change request for OMB No. 0920-0728, expiration date 07/31/2025, for the reporting of Nationally Notifiable Diseases. Information on proposed disease-specific data elements to be added through this non-substantive change request is enumerated in the table below:

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Disease Name**  **in NNDSS Collection** | Nationally Notifiable (NNC) OR Under Standardized Surveillance (CSS) | Current Case Notification (Y/N) | Proposed Case Notification (Y/N) | Current Disease-specific Data Elements (Y/N) | Proposed Disease-specific Data Elements (Y/N) | Number of Existing Data Elements in NNDSS | Proposed Number of new NNDSS Data Elements |
| Arboviral | NNC |  |  | Y | Y | 159 | 8 |
| Carbon Monoxide Poisoning | NNC |  |  | Y | Y | 50 | 13 |
| Hepatitis | NNC |  |  | Y | Y | 190 | 8 |
| Malaria | NNC |  |  | Y | Y | 100 | 1 |
| Monkeypox | NNC |  |  | N | Y | 0 | 59 |

The National Notifiable Diseases Surveillance System (NNDSS) is the nation’s public health surveillance system that enables all levels of public health (local, state, territorial, federal and international) to monitor the occurrence and spread of the diseases and conditions that CDC and the Council of State and Territorial Epidemiologists (CSTE) officially designate as “nationally notifiable” or as under “standardized surveillance.” The NNDSS program creates the infrastructure for the surveillance system and facilitates the submission and aggregation of case notification data voluntarily submitted to CDC from 60 jurisdictions: public health departments in every U.S. state, New York City, Washington DC, 5 U.S. territories (American Samoa, the Commonwealth of Northern Mariana Islands, Guam, Puerto Rico, and the U.S. Virgin Islands), and 3 freely associated states (Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau). The NNDSS also facilitates relevant data management, analysis, interpretation and dissemination of the information. The data are used to monitor the occurrence of notifiable conditions and to plan and conduct prevention and control programs at the state, territorial, local and national levels.

This request is for the addition of 89 new disease-specific data elements: 8 new disease-specific data elements for Arboviral, 13 new disease-specific data elements for Carbon Monoxide Poisoning, 8 new disease-specific data elements for Hepatitis, 1 new disease-specific data element for Malaria, and 59 new disease-specific data elements for Monkeypox.

|  |  |
| --- | --- |
| **Arboviral** |  |
| The impetus/urgency for CDC to add data elements for this condition | * To better align arboviral surveillance data collection with current practices for other notifiable conditions. Harmonization should decrease burden on jurisdictional public health partners in reporting notifiable conditions to CDC * To provide more information about vaccination history among arboviral disease cases |

|  |  |  |  |
| --- | --- | --- | --- |
| **Data Element Name** | **Data Element Description** | **Value Set Code** | **CDC Priority[[1]](#footnote-1)** |
| Type of Complication | If the subject experienced severe complications due to this illness, specify the complication(s). | TBD | 2 |
| Type of Complications Indicator | Indicator for associated complication | PHVS\_YesNoUnknown\_CDC | 2 |
| Signs and Symptoms | Sign and symptoms associated with the illness being reported | TBD | 2 |
| Signs and Symptoms Indicator | Indicator for associated signs and symptoms | PHVS\_YesNoUnknown\_CDC | 2 |
| Clinical Finding | Clinical findings associated with the illness being reported | TBD | 2 |
| Clinical Finding Indicator | Indicator for associated clinical findings | PHVS\_YesNoUnknown\_CDC | 2 |
| Transmission Mode Detail | For rare arboviral transmission modes, indicate the determined source of infection following investigation of the case. | TBD | 2 |
| Manufacturer of Last Dose Prior to Illness Onset | Manufacturer of last vaccine dose against this disease prior to illness onset | TBD | 2 |

|  |  |
| --- | --- |
| **Carbon Monoxide Poisoning** |  |
| The impetus/urgency for CDC to add data elements for this condition | * To make surveillance more comprehensive and informative for public health actions including public health policy. * Enhanced surveillance to learn about the effects of long-term exposures to low levels of CO, and monitor trends identify high risk groups. * Additional data would help to better targe outreach activities to those at increased risk for CO poisoning. |

|  |  |  |  |
| --- | --- | --- | --- |
| **Data Element Name** | **Data Element Description** | **Value Set Code** | **CDC Priority[[2]](#footnote-2)** |
| Severe Weather | Was the carbon monoxide exposure related to a severe weather event? | PHVS\_YesNoUnknown\_CDC | 1 |
| Severe Weather Type | Identify the severe weather event(s) occurring when the patient was exposed to carbon monoxide. | TBD | 1 |
| Intent of Exposure | Was the intent of the carbon monoxide exposure self-harm/assault (intentional) or accidental (unintentional)? | TBD | 1 |
| Carbon Monoxide Level in Air | Carbon monoxide level in air measured in parts per million (PPM) at exposure site | N/A | 3 |
| Start Date of Treatment or Therapy | Provide the date and time of when the treatment started. | N/A | 2 |
| Underlying Condition(s) Indicator | Indicator for underlying condition(s) | PHVS\_YesNoUnknown\_CDC | 2 |
| Signs and Symptoms Indicator | Indicator for associated sign and symptom | PHVS\_YesNoUnknown\_CDC | 1 |
| Specimen Collection Date/Time | Date of collection of laboratory specimen used for diagnosis of health event reported in this case report. Time of collection should be sent if available. | N/A | 2 |
| Start Date of Treatment or Therapy | Provide the date and time of when the treatment started. | N/A | 2 |
| Type of Workers Compensation Claim | Indicate if the worker's compensation claim is submitted or paid with a finding, problem, diagnosis or other indication of exposure to carbon monoxide or carbon monoxide poisoning. | TBD | 2 |
| Test Type | Please specify Carboxyhemoglobin Level or Pulse CO-oximetry Measurement test. | TBD | 1 |
| Test Result Quantitative | Please send the test results for the selected test type. The unit of test result is percent (%). | N/A | 2 |
| Specimen Collection Date/Time | Date of collection of laboratory specimen used for diagnosis of health event reported in this case report. Time of collection should be sent if available. | N/A | 2 |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Hepatitis** |  | | | |
| The impetus/urgency for CDC to add data elements for this condition | * The data elements included in this change request will contribute to enhanced surveillance efforts for those jurisdictions funded through PS21-2103 “Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments”. * These data elements will improve standardization of data collection for CDC surveillance and improve the overall understanding of the population and factors contributing to viral hepatitis infection. The enhanced surveillance will be more comprehensive and informative for public health actions and will improve guidance on infection control and prevention. | | | |
| **Data Element Name** | | **Data Element Description** | **Value Set Code** | **CDC Priority (New)** |
| Alanine Aminotransferase (ALT) Result | | What was the patient’s ALT level (IU/L)?  Note: The result of the ALT test performed on the same specimen as the positive hepatitis A, B or C lab result(s) or associated with the positive hepatitis A, B or C lab result(s).  CDC’s preference is for the qualitative result to be submitted when available rather than the quantitative option. | PHVS\_AlanineATResult\_Hepatitis | 2 |
| Vaccine Series Completed | | Was the vaccine series completed? | PHVS\_YesNoUnknown\_CDC | 2 |
| Donor Screening | | Patient was determined to have viral hepatitis during screening for blood, organ, or tissue donation. Please indicate the donation type. | PHVS\_DonorScreening\_Hepatitis | 2 |
| Travel Outside USA Prior to Illness Onset (within Program Specific Timeframe) | | Did the patient travel or live internationally in the 15 to 50 days before symptom onset date?  Note: If the symptom onset date is unknown, then the date that the patient first tested positive for hepatitis A virus (HAV) can be used as a proxy for symptom onset date. | PHVS\_YesNoUnknown\_CDC | 1 |
| Specify Different Travel Exposure Window | | If the travel exposure window used by the jurisdiction is different from that stated in the travel exposure questions, specify the time interval in days here. Otherwise, leave blank. | N/A (text field) | 1 |
| International Destination(s) of Recent Travel | | International destination or countries the patient traveled to or lived in, in the 15 to 50 days before symptom onset  Note: If the symptom onset date is unknown, then the date that the patient first tested positive for hepatitis A virus (HAV) can be used as a proxy for symptom onset date. | PHVS\_Country\_ISO\_3166-1 | 1 |
| Date of Arrival to Travel Destination | | Date of arrival to travel destination | N/A (Date) | 3 |
| Date of Departure from Travel Destination | | Date of departure from travel destination | N/A (Date) | 3 |

|  |  |
| --- | --- |
| **Malaria** |  |
| The impetus/urgency for CDC to add data elements for this condition | * Link reported congenital malaria cases to the mother’s reported malaria case to gain a better understanding and more complete picture of risk factors. * Assist in improving CDC’s epidemiologic understanding of the rare condition of congenital malaria and disease trends over time. |

|  |  |  |  |
| --- | --- | --- | --- |
| **Data Element Name** | **Data Element Description** | **Value Set Code** | **CDC Priority (New)** |
| Mother's Local Record ID | Provide the local record ID used for reporting mother's case (DE Identifier "N/A: OBR-3" in the Generic portion of the message). This will be used for linking the reported congenital case to the mother's reported case. | N/A | 3 |

|  |  |
| --- | --- |
| **Monkeypox** |  |
| The impetus/urgency for CDC to add data elements for this condition | * Since January 2022, clusters of monkeypox cases, have been reported in 71 countries that do not normally have monkeypox. As of this writing (29 July, 2022) there are over 21,148 confirmed cases globally. The number of confirmed cases in the U.S. is rapidly increasing. Since January, 4,906 confirmed cases in the U.S. have been identified. Most of U.S. cases do not have direct travel-associated exposure risks (i.e., travel to monkeypox endemic countries). Transmission during close contact and intimate contact is thought to be a major transmission route. * NNDSS reporting will enhance the speed, accuracy, and comparability of data capture for monkeypox case notifications during this outbreak, particularly as new states are onboarded. * Data collected will inform public health interventions to interrupt disease transmission and identify risk factors for infection. |

|  |  |  |  |
| --- | --- | --- | --- |
| **Data Element Name** | **Data Element Description** | **Value Set Code** | **CDC Priority**  **(New)** |
| Tribal Residence | If you reside in a Tribal Area, please specify | TBD | 2 |
| Tribal Name | If the selected race is American Indian or Alaska Native, what is the tribal affiliation? | PHVS\_TribeName\_NND | 3 |
| Gender Identity | Do you currently describe yourself as male, female, or transgender? | PHVS\_GenderIdentity\_USCDI | 1 |
| Sexual Orientation | Patient identified sexual orientation (i.e., an individual's physical and/or emotional attraction to another individual of the same gender, opposite gender, or both genders). | PHVS\_SexualOrientation\_USCDI | 2 |
| Birth Sex | What sex were you assigned at birth, on your original birth certificate? | PHVS\_Sex\_MFU | 1 |
| Reason Vaccine Administered | Reason individual received a vaccine against this condition | TBD | 2 |
| Sexual Contact | Did you engage in any sex and/or close intimate contact before your first symptom appeared? | PHVS\_YesNoUnknown\_CDC | 2 |
| Sex with Male Partners | Sex with male partners? | PHVS\_YesNoUnknown\_CDC | 2 |
| Number of Male Sexual Partners | Number of male partners or description if no number is provided | N/A | 2 |
| Numerical Range of Male Partners | If individual is unable to specify, provide a range of options for the number of male partners | TBD | 2 |
| Sex with Female Partners | Sex with female partners? | PHVS\_YesNoUnknown\_CDC | 2 |
| Number of Female Sexual Partners | Number of female partners or description if no number is provided | N/A | 2 |
| Numerical Range of Female Partners | If individual is unable to specify, provide a range of options for the number of female partners | TBD | 2 |
| Sex with Transgender Female Partners | Sex with transgender female partners? | PHVS\_YesNoUnknown\_CDC | 2 |
| Number of Transgender Female Partners | Number of transgender female partners or description if no number is provided | N/A | 2 |
| Numerical Range of Female Transgender Partners | If individual is unable to specify, provide a range of options for the number of transgender female partners | TBD | 2 |
| Sex with Transgender Male Partners | Sex with transgender male partners? | PHVS\_YesNoUnknown\_CDC | 2 |
| Number of Transgender Male Partners | Number of transgender male partners or description if no number is provided | N/A | 2 |
| Numerical Range of Transgender Male Partners | If individual is unable to specify, provide a range of options for the number of transgender male partners | TBD | 2 |
| Sex with Other Gender Identity Partners | Sex with other gender identity partners? | PHVS\_YesNoUnknown\_CDC | 2 |
| Number of Other Gender Identity Partners | Number of other gender identity partners or description if no number is provided | N/A | 2 |
| Numerical Range of Other Identity Gender Partners | If individual is unable to specify, provide a range of options for the number of other gender identity partners | TBD | 2 |
| Epi Linked | Specify if this case is epidemiologically linked to another confirmed or probable case | PHVS\_YesNoUnknown\_CDC | 1 |
| CDC Event Case ID | This ID is used to track information about the case-patient in CDC data systems and must be provided on all forms or specimens related to this individual | N/A | 3 |
| Linked Case Number | Provide State assigned Case ID | N/A | 3 |
| Contact Type | Type of contact | TBD | 1 |
| Specify Other Contact Type | Other contact type | N/A | 1 |
| Did The Case Travel Domestically Prior To Illness Onset? | Did you spend time (within the US) outside your home state or territory during the [time period] before your first symptom appeared (also called symptom onset)? | PHVS\_YesNoUnknown\_CDC | 3 |
| Travel State | State traveled to | PHVS\_State\_FIPS\_5-2 | 3 |
| Date Of Departure From Travel Destination | Date of departure (MM/DD/YYYY) | N/A | 3 |
| Date Of Arrival To Travel Destination | Date of return (MM/DD/YYYY) | N/A | 3 |
| Sexual Contact During Domestic Travel | Did you have intimate or sexual contact with new partners on domestic trip? | PHVS\_YesNoUnknown\_CDC | 3 |
| Domestic Travel Comment | Any additional comments on travel within the US that may be important | N/A | 3 |
| Travel Outside USA Prior To Illness Onset Within Program Specific Timeframe | Did you spend time in a country outside the US during the [time period] before your first symptom appeared (also called symptom onset)? | PHVS\_YesNoUnknown\_CDC | 3 |
| International Destination(s) of Recent Travel | Country traveled to | PHVS\_Country\_ISO\_3166-1 | 3 |
| Sexual Contact During International Travel | Did you have any intimate or sexual contact with new partners on international trip? | PHVS\_YesNoUnknown\_CDC | 3 |
| International Travel Comment | Any additional comments on travel outside the US that may be important? | N/A | 3 |
| Case Patient a Healthcare Worker | Is this individual a health care worker who was exposed at work? | PHVS\_YesNoUnknown\_CDC | 1 |
| Location of Exposure | Please provide the suspect location of exposure | TBD | 1 |
| Exposure Comment | Please provide any additional details on the location of exposure (e.g., health care setting, large gathering, private party) | N/A | 1 |
| Number of Household Contacts | Please provide the number of identified contacts this case may have exposed (either named or anonymous) | N/A | 2 |
| Signs and Symptoms | Signs and symptoms associated with the illness being reported | TBD | 3 |
| Signs and Symptoms Indicator | Indicator for associated sign and symptom | PHVS\_YesNoUnknown\_CDC | 3 |
| Skin Lesion(s) (disorder) | Did you have a rash during the course of your illness? | PHVS\_YesNoUnknown\_CDC | 3 |
| Rash Onset Date | If yes, what was the date of rash onset (i.e., the date the rash first appeared)? | N/A | 3 |
| Body Region(s) of Rash | If yes, where on your body is the rash? (choose all that apply) | TBD | 3 |
| Ocular Manifestations | Any evidence of ocular involvement (ocular lesions, keratitis, conjunctivitis, eyelid lesions)? | TBD | 3 |
| Co-infection | Has this individual been diagnosed with any acute infections other than [condition] during this current illness/or within [time period]? | PHVS\_YesNoUnknown\_CDC | 3 |
| Co-infection Type | Specify other co-infections | TBD | 3 |
| HIV Status | What is the individual's HIV status? | PHVS\_HIVStatus\_STD | 1 |
| HIV Viral Load Undetectable | If HIV positive, was the individual's viral load undetectable when it was last checked? | PHVS\_YesNoUnknown\_CDC | 2 |
| Patient Immunocompromised | Does the individual have any known immunocompromising conditions (excluding HIV) or take immunosuppressive medications? | PHVS\_YesNoUnknown\_CDC | 1 |
| Immunocompromised Condition or Treatment | Describe the associated immunocompromising condition or treatment | TBD | 1 |
| Reason for Hospitalization | Reason for the hospitalization? (choose all that apply) | TBD | 2 |
| Receiving HIV Pre-exposure Prophylaxis | Is the individual currently receiving HIV pre-exposure prophylaxis? | PHVS\_YesNoUnknown\_CDC | 2 |
| Currently Breastfeeding | Are you currently breastfeeding? | PHVS\_YesNoUnknown\_CDC | 2 |
| Household pets | Do any pets live in your household? | PHVS\_YesNoUnknown\_CDC | 2 |
| Type of animal(s) | Which type of animal(s) in household? (select all that apply) | TBD | 2 |
| Other pet(s) | Please specify other pet(s) | N/A | 2 |

Burden

The burden to add 89 data elements to NNDSS is applicable to all 50 states, 5 territories, 3 freely associated states, and 2 cities. Although not all territories and freely associated states use electronic, automated transmission for their case notifications, it is expected that they will adopt electronic, automated transmission in the next three years. This burden includes the one-time burden incurred by the respondents to add the data elements to their surveillance system and modify their case notification message. A one-time average burden of 9 hours is incurred for respondents to add 89 data elements to their surveillance system and modify their electronic case notification message to accommodate those 89 additional data elements. This one-time burden of 9 hours is noted in the following table

One-Time Burden to Add 89 Data Elements to NNDSS:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Type of Respondents** | **Number of Respondents** | **Number of Responses per Respondent** | **Average Burden Per Response (in hours): One-time Addition of 89 Data Elements** |  |
| States | 50 | 1 | 9 |  |
| Territories | 5 | 1 | 9 |  |
| Freely Associated States | 3 | 1 | 9 |  |
| Cities | 2 | 1 | 9 |  |
| Total |  |  |  |  |

The total annualized one-time burden is 180 hours (150 hours for states, 15 hours for territories, 9 hours for freely associated states and 6 hours for cities) as noted in the table below.

Annualized One-Time Burden to Add 89 Data Elements to NNDSS

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Type of Respondents** | **Number of Respondents** | **Number of Responses per Respondent** | **Average Burden Per Response (in hours): Annualized One-time Addition of 89 Data Elements** | **Total Annualized One-Time Burden (in hours)** |
| States | 50 | 1 | 3 | 150 |
| Territories | 5 | 1 | 3 | 15 |
| Freely Associated States | 3 | 1 | 3 | 9 |
| Cities | 2 | 1 | 3 | 6 |
| Total |  |  |  | 180 |

180 hours were added to the existing burden hours in Table A.12A and Table A.12B below.

A.12A. Estimates of Annualized Burden Hours

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Type of Respondents** | **Form Name** | **Number of Respondents** | **Number of Responses per Respondent** | **Average Burden Per Response (in hours)** | **Total Burden (in hours)** |
| States | Weekly (Automated) | 50 | 52 | 20/60 | 867 |
| States | Weekly (Non- automated) | 10 | 52 | 2 | 1,040 |
| States | Weekly (NMI Implementation) | 50 | 52 | 4 | 10,400 |
| States | Annual | 50 | 1 | 75 | 3,750 |
| States | One-time Addition of Diseases and Data Elements | 50 | 1 | 4 | 200 |
| Territories | Weekly (Automated) | 5 | 52 | 20/60 | 87 |
| Territories | Weekly, Quarterly (Non-automated) | 5 | 56 | 20/60 | 93 |
| Territories | Weekly (NMI Implementation) | 5 | 52 | 4 | 1,040 |
| Territories | Annual | 5 | 1 | 5 | 25 |
| Territories | One-time Addition of Diseases and Data Elements | 5 | 1 | 4 | 20 |
| Freely Associated States | Weekly (Automated) | 3 | 52 | 20/60 | 52 |
| Freely Associated States | Weekly, Quarterly (Non-automated) | 3 | 56 | 20/60 | 56 |
| Freely Associated States | Annual | 3 | 1 | 5 | 15 |
| Freely Associated States | One-time Addition of Diseases and Data Elements | 3 | 1 | 4 | 12 |
| Cities | Weekly (Automated) | 2 | 52 | 20/60 | 35 |
| Cities | Weekly (Non-automated) | 2 | 52 | 2 | 208 |
| Cities | Weekly (NMI Implementation) | 2 | 52 | 4 | 416 |
| Cities | Annual | 2 | 1 | 75 | 150 |
| Cities | One-time Addition of Diseases and Data Elements | 2 | 1 | 4 | 8 |
| **Total** |  |  |  |  | **18,474** |

A.12B. Estimates of Annualized Cost Burden

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Type of Respondents** | **Form Name** | **Number of Respondents** | **Number of Responses per Respondent** | **Average Burden Per Response (in hours)** | **Total Burden Hours** | **Hourly Wage Rate** | **Respondent Cost** |
| States | Weekly (Automated) | 50 | 52 | 20/60 | 867 | $49.14 | $42,604 |
| States | Weekly (Non-automated) | 10 | 52 | 2 | 1,040 | $41.70 | $43,368 |
| States | Weekly (NMI Implementation) | 50 | 52 | 4 | 10,400 | $49.14 | $511,056 |
| States | Annual | 50 | 1 | 75 | 3,750 | $41.70 | $156,375 |
| States | One-time Addition of Diseases and Data Elements | 50 | 1 | 4 | 200 | $49.14 | $9,828 |
| Territories | Weekly (Automated) | 5 | 52 | 20/60 | 87 | $49.14 | $4,275 |
| Territories | Weekly, Quarterly (Non-automated) | 5 | 56 | 20/60 | 93 | $41.70 | $3,878 |
| Territories | Weekly (NMI Implementation) | 5 | 52 | 4 | 1,040 | $49.14 | $51,106 |
| Territories | Annual | 5 | 1 | 5 | 25 | $41.70 | $1,043 |
| Territories | One-time Addition of Diseases and Data Elements | 5 | 1 | 4 | 20 | $49.14 | $982.80 |
| Freely Associated States | Weekly (Automated) | 3 | 52 | 20/60 | 52 | $49.14 | $2,555 |
| Freely Associated States | Weekly, Quarterly (Non-automated) | 3 | 56 | 20/60 | 56 | $41.70 | $2,335 |
| Freely Associated States | Annual | 3 | 1 | 5 | 15 | $41.70 | $626 |
| Freely Associated States | One-time Addition of Diseases and Data Elements | 3 | 1 | 4 | 12 | $49.14 | $589.68 |
| Cities | Weekly (Automated) | 2 | 52 | 20/60 | 35 | $49.14 | $1,720 |
| Cities | Weekly (Non-automated) | 2 | 52 | 2 | 208 | $41.70 | $8,674 |
| Cities | Weekly (NMI Implementation) | 2 | 52 | 4 | 416 | $49.14 | $20,442 |
| Cities | Annual | 2 | 1 | 75 | 150 | $41.70 | $6,255 |
| Cities | One-time Addition of Diseases and Data Elements | 2 | 1 | 4 | 8 | $49.14 | $393.12 |
| **Total** |  |  |  |  |  |  | **$868,106** |

1. R=Required; 1=Priority 1, 2=Priority 2, 3=Priority 3 [↑](#footnote-ref-1)
2. R=Required; 1=Priority 1, 2=Priority 2, 3=Priority 3 [↑](#footnote-ref-2)